مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
Clinical Significance of Reduced FAM181B Expression in Papillary Thyroid Carcinoma
Clinical Significance of Reduced FAM181B Expression in Papillary Thyroid Carcinoma
Matin Bohlooli,1Seyed Morteza Javadi Rad,2,*
1. MS student, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, 81746-73441, Isfahan, Iran. matin.bohlooli.ui@gmail.com 2. Assistant Professor of Molecular Genetics, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, 81746-73441, Isfahan, Iran. javadirad@yahoo.com
Introduction: Papillary thyroid carcinoma (PTC) is classified as a well-differentiated cancer and is one of the most prevalent forms of thyroid cancer. The etiology of PTC is significantly influenced by genetic and environmental factors. However, the precise genetic underpinnings of this malignancy are still incompletely understood, despite the extensive investigation of numerous PTC-associated genes. The objective of this investigation was to identify critical genes that are associated with clinical outcomes in PTC.
Methods: The GSE104005 dataset, comprising 19 PTC tissue samples and 5 neighboring normal thyroid tissues, was examined. Log2 transformation was utilized to assess data quality, subsequently followed by principal component analysis (PCA). The Limma software was utilized for differential expression analysis. Genes exhibiting a logFC greater than 1.2 and adjusted p-values less than 0.05 were selected as differentially expressed genes (DEGs). Moreover, RNA-seq data were examined utilizing the UALCAN database, and assessments of patient survival, cancer stage, and lymph node metastasis were performed. 10 papillary thyroid carcinoma (PTC) specimens and 10 neighboring normal specimens were obtained during thyroid surgery. Total RNA extraction, complementary DNA synthesis, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) will be conducted.
Results: Familial Sequence Homology 181 Member B (FAM181B) was recognized as a differentially expressed gene in the microarray data analysis, exhibiting a logFC of -2.71 (adjusted p-value of 2.3E-05). Elevated FAM181B expression, as opposed to low or medium expression, was substantially correlated with reduced patient survival probability (p-value of 7.8E-04). The expression of FAM181B was assessed at various biological stages, revealing a median expression level of 0.86 in Stage 2 and 0.369 in Stage 4. Our findings demonstrated that FAM181B expression in Stages 2 and 4 substantially linked with heightened aggression (P-value of 1.06E-03). The median expression level of FAM181B in tumors devoid of regional lymph node infiltration (N0) was 0.735, but it was 0.462 in tumors with axillary lymph node metastases (N1). Analyses demonstrated a statistically significant difference in FAM181B expression between N0 and N1 tumors (p-value of 1.04E-04). No statistically significant disparity in FAM181B expression was detected between male and female patients.
Conclusion: The FAM181B gene exhibited a significant reduction in expression in PTC compared to the surrounding normal tissues adjacent to PTC tumors. The reduced expression of FAM181B was associated with improved patient survival and metastasis.